tiprankstipranks
APONTIS PHARMA AG (DE:APPH)
XETRA:APPH
Germany Market
Holding DE:APPH?
Track your performance easily

APONTIS PHARMA AG (APPH) Income Statement

7 Followers

APONTIS PHARMA AG Income Statement

Last quarter (Q4 2022), APONTIS PHARMA AG's total revenue was €―, a decrease of ― from the same quarter last year. In Q4, APONTIS PHARMA AG's net income was €―. See APONTIS PHARMA AG’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
-€ 55.73M€ 51.18M€ 39.24M€ 40.04M€ 11.73M
Cost of Revenue
-€ 20.74M€ 17.40M€ 14.22M€ 11.06M€ 3.69M
Gross Profit
-€ 34.99M€ 33.79M€ 25.03M€ 28.97M€ 8.05M
Operating Expense
-€ 31.18M€ 32.12M€ 25.64M€ 31.21M€ 7.41M
Operating Income
-€ 3.81M€ 1.67M€ -614.40K€ -2.24M€ 640.58K
Net Non Operating Interest Income Expense
-€ 15.91K€ -401.35K€ -863.03K€ -827.77K€ -218.98K
Other Income Expense
------
Pretax Income
-€ 3.83M€ 248.26K€ -1.48M€ -3.07M€ 421.61K
Tax Provision
-€ 1.14M€ 993.53K€ -294.73K€ -678.00K€ 165.22K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-€ 2.69M€ -745.24K€ -1.18M€ -2.39M€ 256.55K
Basic EPS
-€ 0.32€ -0.09€ -0.14€ -0.28€ 0.03
Diluted EPS
-€ 0.32€ -0.09€ -0.14€ -0.28€ 0.03
Basic Average Shares
-€ 8.50M€ 8.50M€ 8.50M€ 8.50M€ 8.50M
Diluted Average Shares
-€ 8.50M€ 8.50M€ 8.50M€ 8.50M€ 8.50M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-€ 51.91M€ 49.52M€ 39.85M€ 42.28M€ 11.09M
Net Income From Continuing And Discontinued Operation
-€ 2.69M€ -745.24K€ -1.18M€ -2.39M€ 256.55K
Normalized Income
-€ 2.69M€ -33.34K€ -1.18M€ -2.39M€ 256.55K
Interest Expense
-€ 48.00K€ 406.00K€ 868.00K€ 828.00K€ 215.00K
EBIT
-€ 3.88M€ 654.26K€ -609.42K€ -2.24M€ 636.61K
EBITDA
-€ 5.67M€ 2.40M€ 1.04M€ -1.67M€ 701.61K
Currency in EUR

APONTIS PHARMA AG Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis